GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $30.3750.

A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of GH Research in a report on Wednesday, October 8th. Zacks Research lowered shares of GH Research from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. JMP Securities reiterated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a report on Tuesday, June 24th. Finally, Needham & Company LLC started coverage on shares of GH Research in a report on Monday. They set a "buy" rating and a $19.00 price objective for the company.

GH Research Trading Down 2.4%

GH Research stock opened at $13.49 on Friday. The firm has a 50-day moving average price of $13.26 and a 200-day moving average price of $12.52. The firm has a market capitalization of $701.88 million, a PE ratio of -18.23 and a beta of 0.97. GH Research has a 12-month low of $6.72 and a 12-month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. As a group, sell-side analysts predict that GH Research will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in GHRS. Cormorant Asset Management LP increased its position in GH Research by 238.8% during the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock valued at $22,165,000 after purchasing an additional 1,416,439 shares during the period. Jefferies Financial Group Inc. purchased a new position in GH Research during the 1st quarter valued at about $8,272,000. Alyeska Investment Group L.P. purchased a new position in GH Research during the 1st quarter valued at about $5,018,000. RA Capital Management L.P. increased its position in GH Research by 3.9% during the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock valued at $76,599,000 after purchasing an additional 257,959 shares during the period. Finally, Troluce Capital Advisors LLC purchased a new position in GH Research during the 1st quarter valued at about $1,716,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.